Browse the evidence

Tirzepatide, a dual GLP-1/GIP receptor agonist, produces significantly greater body weight reduction (up to 20.9% at 15mg) compared to semaglutide and other GLP-1 agonists in patients with obesity, with real-world studies confirming superior efficacy.

Tirzepatide (up to 15mg once weekly) is the most effective current pharmacological treatment for obesity, producing up to 21% weight loss. Real-world data shows it outperforms semaglutide. Discuss side effects like nausea with your provider, and consider cost-effectiveness as data is still emerging.

Retatrutide, a triple agonist targeting GLP-1, GIP, and glucagon receptors, produces superior mean weight loss (up to 24.2%) and metabolic improvements compared to placebo and existing dual agonists in phase 2 trials for obesity and type 2 diabetes.

Retatrutide is a once-weekly injection that targets three hormones to significantly reduce body weight and improve blood sugar control. In clinical trials, it led to an average 24% weight loss in people with obesity over 48 weeks. Common side effects like nausea are manageable with dose titration. It is currently in phase 3 trials for broader approval.

High-dose GLP-1 receptor agonists (e.g., semaglutide 2.4mg) and dual GLP-1/GIP agonists (e.g., tirzepatide) are effective for treating prediabetes by inducing significant weight loss (15-20%), which reduces insulin resistance and lowers diabetes risk.

If you have prediabetes and struggle to lose weight, high-dose GLP-1 or GLP-1/GIP injections (like semaglutide or tirzepatide) are highly effective. They cause significant weight loss (15-20%), which fixes the underlying insulin resistance and reduces diabetes risk. You likely need to stay on them long-term to keep the weight off.

Tirzepatide induces significant weight reduction in individuals with obesity caused by pathogenic MC4R mutations, achieving efficacy comparable to non-carriers.

If you have obesity caused by an MC4R mutation, tirzepatide is a highly effective treatment option. Clinical data shows you will likely lose a significant amount of weight (around 18%) over 72 weeks, similar to people without this genetic mutation. Because lifestyle changes alone are often insufficient for this specific genetic profile, pharmacological intervention with tirzepatide is recommended to manage severe obesity and its complications.

Carrying the T allele of the GLP1R missense variant rs10305420 (p.Pro7Leu) significantly increases weight loss efficacy in patients treated with GLP-1 receptor agonists, adding approximately 0.76 kg of weight loss per allele copy.

If you are taking a GLP-1 medication like semaglutide or tirzepatide, your genetics play a role in how much weight you lose. Specifically, a common genetic variant (rs10305420) is linked to better weight loss results. While this genetic effect is modest (adding less than 1 kg on average), it is a real biological factor. This suggests that genetic testing could eventually help doctors predict who will respond best to which drug, allowing for more personalized treatment plans rather than a one-size-fits-all approach.

Once-weekly efpeglenatide significantly reduces HbA1c and body weight in patients with type 2 diabetes and obesity, with a safety profile characterized by mild-to-moderate gastrointestinal side effects and low hypoglycemia risk.

Efpeglenatide is a once-weekly (or monthly) injection that helps lower blood sugar and lose weight in people with type 2 diabetes and obesity. It is generally well-tolerated, with common side effects like nausea being mild and temporary. It offers a convenient alternative to daily medications and has cardiovascular benefits for high-risk patients.

Cagrilintide, a long-acting amylin analogue, produces dose-dependent weight loss in adults with obesity, with the highest dose (4.5 mg) showing greater weight loss than Liraglutide 3.0 mg.

Cagrilintide is a once-weekly injection that mimics the hormone amylin to reduce appetite and slow digestion. In a 26-week trial, the highest dose (4.5 mg) led to an average 10.8% weight loss, outperforming Liraglutide 3.0 mg. It is currently in Phase 2 development for adults with obesity.

Orlistat reduces the incidence of type 2 diabetes in individuals with prediabetes or impaired glucose tolerance by approximately 37% over four years compared to placebo when combined with lifestyle changes.

If you are overweight and have prediabetes, adding orlistat (120mg with meals) to your lifestyle changes can significantly lower your risk of developing full-blown type 2 diabetes compared to lifestyle changes alone. Be mindful of your fat intake to minimize gastrointestinal side effects.

Anti-obesity medications (AOMs), particularly GLP-1 and dual GIP/GLP-1 agonists, produce significant weight loss (5-20%+) and should be continued long-term as disease-modifying agents rather than short-term aids.

If you have obesity or overweight with related health issues, talk to your doctor about long-term medication options like GLP-1 agonists. These are not quick fixes but chronic disease treatments. Expect to start with a low dose to minimize stomach issues and increase it slowly. You must combine this with lifestyle changes for the best results, and do not stop the medication once you reach your goal, as stopping often leads to regaining the weight.

Gut hormone-based pharmacotherapies (GLP-1RAs, amylin analogues, and multi-agonists) produce clinically significant weight loss (≥10-15%) and improve cardiometabolic health, effectively closing the treatment gap between lifestyle interventions and bariatric surgery.

For individuals with obesity who have not achieved sufficient weight loss through lifestyle changes alone, gut hormone-based medications (like semaglutide or tirzepatide) offer a clinically effective treatment option that can produce 10-15% or more weight loss. These treatments work by targeting the body's natural appetite-regulating systems, mimicking the effects of bariatric surgery to a degree, and improving metabolic health. While side effects like nausea are common, they often subside with dose titration, and new oral formulations are emerging to address injection aversion.

Combination therapies targeting multiple gut hormone pathways (e.g., GLP-1 + Amylin, GLP-1 + GIP, GLP-1 + GIP + Glucagon) show superior weight loss efficacy compared to monotherapies, approaching the magnitude of weight loss seen after bariatric surgery.

For patients who do not achieve sufficient weight loss with single-agent GLP-1 therapy, combination treatments (like CagriSema or Tirzepatide) offer a powerful alternative. These drugs target multiple hormonal pathways simultaneously, resulting in greater weight loss (up to 17% or more in trials) than monotherapies alone. This approach narrows the gap between medication and surgery, offering a viable option for those with severe obesity.

Tirzepatide, a GLP1:GIP dual agonist, provides superior glycemic and weight-loss efficacy compared to placebo, achieving >20% body weight loss in 57% of participants at the highest dose over 72 weeks.

Tirzepatide, a dual GLP1:GIP agonist, has demonstrated superior efficacy in Phase 3 trials, achieving over 20% body weight loss in more than half of participants at the highest dose over 72 weeks with minimal side effects. This makes it a highly effective option for managing diabesity compared to placebo.

Higher protein intake (≥25% TDE or ≥1.25 g/kg/day) during energy restriction promotes greater fat loss and fat-free mass preservation compared to standard protein intakes, with modest but clinically relevant long-term weight maintenance benefits.

To maximize fat loss and preserve muscle while dieting, aim for at least 1.25 grams of protein per kilogram of body weight daily, or roughly 25% of your total calories from protein. This approach helps you feel fuller longer and burns slightly more calories through digestion, leading to better fat loss and muscle retention than standard protein intakes.

Daily exercise training (morning or evening) reduces fasting concentrations of large LDL particles (LDL-1) and small HDL particles (HDL-3/4) in men with overweight/obesity, independent of time-of-day.

If you are overweight or obese, engaging in daily exercise (combining high-intensity intervals and moderate cycling) for just 5 days can significantly improve your LDL and HDL particle profiles, regardless of whether you exercise in the morning or evening. Focus on consistency and intensity rather than the specific time of day.

Triple agonist Retatrutide (12 mg/week for 48 weeks) and dual agonist Tirzepatide (15 mg/week for 72 weeks) produce superior weight loss (24.2% and 20.9% respectively) in adults with obesity compared to traditional anti-obesity medications, with even greater effects in those with BMI ≥ 35 kg/m².

Newer drugs like Retratrutide (triple agonist) and Tirzepatide (dual agonist) offer significantly higher weight loss (20-26%) than older drugs. Retratrutide 12mg weekly for 48 weeks and Tirzepatide 15mg weekly for 72 weeks are key examples. These are more effective than traditional options, especially for those with BMI ≥ 35, but cost is a major barrier.

GLP-1 receptor agonists (GLP-1RAs) and sodium-glucose co-transporter-2 inhibitors (SGLT2-is) significantly improve hepatic steatosis and steatohepatitis in patients with MASLD, primarily through weight loss and glycemic control, with some agents also demonstrating antifibrotic properties.

If you have fatty liver disease (MASLD), especially if you also have type 2 diabetes or obesity, GLP-1 receptor agonists (like semaglutide or liraglutide) and SGLT2 inhibitors (like empagliflozin or dapagliflozin) are currently the most effective and accessible pharmaceutical options. They work by improving insulin sensitivity, promoting weight loss, and directly reducing liver fat and inflammation. While they may require injections (for GLP-1RAs) and can cause mild stomach upset, their benefits for both liver and heart health make them a cornerstone of treatment. Always consult your doctor to determine the best option for your specific health profile.

Resistance exercise is the most effective lifestyle intervention for increasing muscle strength in people with type 2 diabetes (T2D), although it may induce an anabolic resistance regarding muscle mass gains compared to healthy controls.

For people with Type 2 Diabetes, resistance training is the best way to build strength. While it might not build as much muscle mass as it does in healthy people (due to 'anabolic resistance'), it is still superior to aerobic exercise for strength. Aim for at least two days a week of resistance training, potentially starting with home-based programs if gym access is a barrier.

Pharmacotherapies for T2D and obesity, specifically GLP-1 receptor agonists (e.g., Tirzepatide) and SGLT2 inhibitors, cause significant loss of lean body mass (20-50% of total weight loss), necessitating concurrent resistance exercise and protein intake to mitigate muscle loss.

If you are taking GLP-1 or SGLT2 medications for diabetes or weight loss, expect to lose some muscle along with fat (up to 50% of the weight). To protect your metabolism and strength, you must combine these medications with resistance exercise and adequate protein intake, as the drugs themselves do not preserve muscle.

Unimolecular GLP1R/GIPR dual agonists (e.g., tirzepatide) produce superior body weight reduction and glycemic improvements compared to GLP-1 receptor agonists alone, driven by GIP receptor signaling in central nervous system GABAergic neurons.

If you are managing obesity or Type 2 Diabetes, dual-acting medications (like tirzepatide) that target both GLP-1 and GIP receptors have shown superior weight loss (up to 20-22%) compared to GLP-1 only drugs. These are taken once weekly. Discuss with your doctor if this option is suitable, noting it may help mitigate some nausea associated with GLP-1 only treatments.

Tirzepatide (5, 10, and 15 mg) achieves stringent glycemic (HbA1c < 5.7% or ≤ 6.5%) and weight loss (≥ 10% or ≥ 15%) targets with a statistically significantly lower cost per responder and lower number needed to treat (NNT) compared to semaglutide 1 mg in patients with type 2 diabetes.

If you have Type 2 Diabetes and are struggling to reach strict blood sugar (HbA1c < 5.7% or ≤ 6.5%) or significant weight loss goals (≥ 10-15%) with metformin, switching to or starting tirzepatide (5-15 mg weekly) is likely more effective and cost-efficient for achieving those specific targets than using semaglutide 1 mg. While tirzepatide has a higher yearly drug price, you are more likely to succeed with it, making it 'cheaper' per successful outcome.

Semaglutide demonstrates superior weight loss and glycemic control compared to other GLP-1RAs like liraglutide and dulaglutide, with weight loss ranging from 10% to over 20%.

Semaglutide (Wegovy) is a once-weekly injection that has shown significant weight loss (10-20%) in clinical trials, outperforming other drugs in its class. It is approved for chronic weight management in adults and adolescents. You must combine it with diet and exercise. Be aware that it is expensive and may face supply shortages due to high demand.

Tirzepatide, a dual GIP and GLP-1 receptor agonist, provides superior weight loss and metabolic improvements compared to selective GLP-1RAs, insulin, and placebo.

Tirzepatide is a once-weekly injection that targets two hormones (GIP and GLP-1) to improve blood sugar and promote weight loss. Clinical trials show weight loss of 15-21% depending on the dose. It is approved for Type 2 Diabetes and is being studied for obesity. It is more effective than some other GLP-1 drugs and insulin in terms of weight loss and metabolic markers.

Tirzepatide, a dual GIP and GLP-1 receptor agonist, provides superior glycemic control and weight reduction compared to semaglutide and insulin in patients with type 2 diabetes.

For patients with type 2 diabetes, especially those with cardiovascular risks or obesity, tirzepatide offers a powerful once-weekly treatment option. It significantly lowers blood sugar and promotes substantial weight loss, often outperforming other common medications like semaglutide or insulin. While cost and injection concerns exist, the clinical benefits for glycemic control and weight management are substantial.

Treatment with semaglutide 2.4 mg for 12 months significantly reduces body weight and improves cardiometabolic risk factors (blood pressure, lipids, HbA1c) in adults with obesity or overweight compared to no obesity medication treatment.

If you have obesity or overweight with related health issues, semaglutide 2.4 mg taken once weekly for a year can lead to significant weight loss (around 15%) and improvements in blood pressure, cholesterol, and blood sugar compared to not using obesity medication. It requires a gradual dose increase to 2.4 mg and should be combined with diet and exercise.